172 related articles for article (PubMed ID: 20140191)
21. TNF receptor gene therapy results in suppression of IgG2a anticollagen antibody in collagen induced arthritis.
Mukherjee P; Wu B; Mayton L; Kim SH; Robbins PD; Wooley PH
Ann Rheum Dis; 2003 Aug; 62(8):707-14. PubMed ID: 12860724
[TBL] [Abstract][Full Text] [Related]
22. Electro-gene therapy of collagen-induced arthritis by using an expression plasmid for the soluble p75 tumor necrosis factor receptor-Fc fusion protein.
Kim JM; Ho SH; Hahn W; Jeong JG; Park EJ; Lee HJ; Yu SS; Lee CS; Lee YW; Kim S
Gene Ther; 2003 Aug; 10(15):1216-24. PubMed ID: 12858186
[TBL] [Abstract][Full Text] [Related]
23. Combined effects of bucillamine and etanercept on a rat type II collagen-induced arthritis model.
Setoguchi C; Tsuji F; Katsuta O; Okamoto M; Aono H
Mod Rheumatol; 2010 Aug; 20(4):381-8. PubMed ID: 20379758
[TBL] [Abstract][Full Text] [Related]
24. Etanercept: a review of its use in the management of rheumatoid arthritis.
Dhillon S; Lyseng-Williamson KA; Scott LJ
Drugs; 2007; 67(8):1211-41. PubMed ID: 17521223
[TBL] [Abstract][Full Text] [Related]
25. [Copernican revolution in the therapy of rheumatoid arthritis: the contribution of anti-TNFalpha drugs].
Bombardieri S; Ferraccioli G; Ferri C; Galeazzi M; Lapadula G; Cerinic MM; Montecucco C; Triolo G; Trotta F; Valentini G
Reumatismo; 2009; 61 Suppl 1():1-23. PubMed ID: 19999184
[TBL] [Abstract][Full Text] [Related]
26. Risk: benefit profile of etanercept in elderly patients with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis.
Fleischmann R; Iqbal I
Drugs Aging; 2007; 24(3):239-54. PubMed ID: 17362051
[TBL] [Abstract][Full Text] [Related]
27. Alleviation of rheumatoid arthritis by cell-transducible methotrexate upon transcutaneous delivery.
Lee SW; Kim JH; Park MC; Park YB; Chae WJ; Morio T; Lee DH; Yang SH; Lee SK; Lee SK; Lee SK
Biomaterials; 2012 Feb; 33(5):1563-72. PubMed ID: 22098778
[TBL] [Abstract][Full Text] [Related]
28. Lentiviral vector-mediated stable expression of sTNFR-Fc in human macrophage and neuronal cells as a potential therapy for neuroAIDS.
Cao S; Wu C; Yang Y; Sniderhan LF; Maggirwar SB; Dewhurst S; Lu Y
J Neuroinflammation; 2011 May; 8():48. PubMed ID: 21569583
[TBL] [Abstract][Full Text] [Related]
29. Biology of TACE inhibition.
Newton RC; Solomon KA; Covington MB; Decicco CP; Haley PJ; Friedman SM; Vaddi K
Ann Rheum Dis; 2001 Nov; 60 Suppl 3(Suppl 3):iii25-32. PubMed ID: 11890648
[TBL] [Abstract][Full Text] [Related]
30. RANKL inhibition by osteoprotegerin prevents bone loss without affecting local or systemic inflammation parameters in two rat arthritis models: comparison with anti-TNFalpha or anti-IL-1 therapies.
Stolina M; Schett G; Dwyer D; Vonderfecht S; Middleton S; Duryea D; Pacheco E; Van G; Bolon B; Feige U; Zack D; Kostenuik P
Arthritis Res Ther; 2009; 11(6):R187. PubMed ID: 20003323
[TBL] [Abstract][Full Text] [Related]
31. Activity study of a hydroxynaphthoquinone fraction from Arnebia euchroma in experimental arthritis.
Fan H; Yang M; Che X; Zhang Z; Xu H; Liu K; Meng Q
Fitoterapia; 2012 Oct; 83(7):1226-37. PubMed ID: 22735599
[TBL] [Abstract][Full Text] [Related]
32. Etanercept: therapeutic use in patients with rheumatoid arthritis.
Garrison L; McDonnell ND
Ann Rheum Dis; 1999 Nov; 58 Suppl 1(Suppl 1):I65-9. PubMed ID: 10577976
[TBL] [Abstract][Full Text] [Related]
33. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease.
Van den Brande JM; Braat H; van den Brink GR; Versteeg HH; Bauer CA; Hoedemaeker I; van Montfrans C; Hommes DW; Peppelenbosch MP; van Deventer SJ
Gastroenterology; 2003 Jun; 124(7):1774-85. PubMed ID: 12806611
[TBL] [Abstract][Full Text] [Related]
34. Pharmacogenetics of etanercept in rheumatoid arthritis.
Danila MI; Hughes LB; Bridges SL
Pharmacogenomics; 2008 Aug; 9(8):1011-5. PubMed ID: 18681777
[TBL] [Abstract][Full Text] [Related]
35. CD200-Fc, a novel antiarthritic biologic agent that targets proinflammatory cytokine expression in the joints of mice with collagen-induced arthritis.
Simelyte E; Criado G; Essex D; Uger RA; Feldmann M; Williams RO
Arthritis Rheum; 2008 Apr; 58(4):1038-43. PubMed ID: 18383359
[TBL] [Abstract][Full Text] [Related]
36. Recombinant human tumor necrosis factor receptor (p75) Fc fusion protein (TNFR:Fc) in rheumatoid arthritis.
Murray KM; Dahl SL
Ann Pharmacother; 1997 Nov; 31(11):1335-8. PubMed ID: 9391689
[TBL] [Abstract][Full Text] [Related]
37. TNF and LT binding capacities in the plasma of arthritis patients: effect of etanercept treatment in juvenile idiopathic arthritis.
Gudbrandsdottir S; Larsen R; Sørensen LK; Nielsen S; Hansen MB; Svenson M; Bendtzen K; Müller K
Clin Exp Rheumatol; 2004; 22(1):118-24. PubMed ID: 15005015
[TBL] [Abstract][Full Text] [Related]
38. [Etanercept: recombinant human soluble tumor necrosis factor receptor fusion protein].
Fujikawa K; Kawakami A; Eguchi K
Nihon Rinsho; 2007 Jul; 65(7):1211-7. PubMed ID: 17642234
[TBL] [Abstract][Full Text] [Related]
39. TNFalpha blockers do not improve the hearing recovery obtained with glucocorticoid therapy in an autoimmune experimental labyrinthitis.
Lobo D; Trinidad A; García-Berrocal JR; Verdaguer JM; Ramírez-Camacho R
Eur Arch Otorhinolaryngol; 2006 Jul; 263(7):622-6. PubMed ID: 16547758
[TBL] [Abstract][Full Text] [Related]
40. Comparisons of affinities, avidities, and complement activation of adalimumab, infliximab, and etanercept in binding to soluble and membrane tumor necrosis factor.
Kaymakcalan Z; Sakorafas P; Bose S; Scesney S; Xiong L; Hanzatian DK; Salfeld J; Sasso EH
Clin Immunol; 2009 May; 131(2):308-16. PubMed ID: 19188093
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
